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Don’t tell anyone but despite all the
razzmatazz the human genome
sequence is not complete. In fact it is
only a ‘working’ draft. There is a
great deal more work to be done to
obtain a complete view of the human
genome as the sequences of only two
human chromosomes — 21 and 22 —
are effectively in the same state as
the other genomes that have been
sequenced so far (Dunham et al.
1999; Hattori et al., 2000).
But alongside the sequencing
work, structural genomics, described
as determining the three-dimensional
structure of proteins in parallel rather
one at a time, has been boosted by
several technical advances, not the
least of which is access to genome
sequences from a growing list of
species.
Protein structures can be very
illuminating from a biochemical
perspective and as more protein
structures are determined the more
useful they will be. One of the most
recent highlights in structural biology
is the high-resolution analysis of the
ribosome (Nissen et al., 2001, but also
see Hendrickson, 2001 for other
important structures).
Being able easily to solve the
structure of proteins is also very
important for drug discovery. Several
drugs, such as inhibitors of the
influenza virus and HIV, were
discovered by systematic analysis of
the molecular interactions between
the potential drug and target protein.
The mechanism of action of a new
inhibitor of c-Abl kinase — STI-571
— was also deduced from a
co-complex of inhibitor and enzyme
(Schindler et al., 2000).
Much has been made of the
rivalry — which still continues —
between the efforts of the public
domain and the private sector in
sequencing the human genome.
Being in the private sector, I was
rather looking forward to comparing
the papers describing the ‘working
drafts’ of the human genome. I have
to say I was somewhat disappointed.
Despite the enormity of the task and
the technical sophistication of the
approaches, seeing our own human
genome sequence in print just did
not do it for me.
I don’t know whether it was the
way the papers were written or the
fact that such a small proportion —
less than 5% — of the genome coded
for proteins that was the problem.
Perhaps it was because it was all
rather dense and essentially not
complete. I expect the mouse genome
sequence to be more interesting. This
sequence will certainly increase the
accuracy of assigning exons to
mammalian genes and comparative
genomics is by its very nature more
revealing (see Rubin et al., 2000).
Even though the two draft human
sequences are similar, the
interpretation of them in the papers
from the two groups was rather
different. In the ‘public’ paper
(International Human Genome
Consortium, 2001) there was an
accent on repeats and genome
evolution while in the ‘commercial’
paper (Venter et al., 2001) there was
more of a concentration on coding
DNA. There were, for example,
useful tables telling us how many
genes there are coding for proteins in
different families. There are thought
now to be over 600 G-protein coupled
receptors (GPCRs). For those
interested in the human genome
sequence from a drug discovery point
of view this is important information.
It is now a requirement to know how
many proteins there are in those
families that are already known to
contain drug targets. GPCRs are the
target for about 50% of all small
molecule drugs. Other important
families include nuclear hormone
receptors, ion channels,
phosphodiesterases, and protein
kinases.
As has been pointed out by many
genome watchers, the conclusion that
there are only 35,000 genes in the
human genome when compared to
the less complex organisms — 19,000
in worm, 14,000 in fly and 7,000 in
yeast — is surprising. But even now,
new genes are being found in these
genomes so it is still an open question
of how many genes there actually are.
One resource that would help
would be to have comprehensive
collections of full-length human
cDNAs such as those being
assembled for the mouse in Japan
(RIKEN, 2001). Some of these
genes, via alternative splicing, will
code for multiple protein products:
the precise relationship between
number of genes and number of
encoded proteins will take some
effort to find out. We are also some
time away from being able to do a
simple database look-up to find
genes in chromosomal regions
involved with susceptibility to
disease, or any other complex trait,
and it is still very difficult to find
these regions.
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From a protein structure
perspective the number of genes in
all these organisms is still, however,
large. There are something in the
order of 15,000 protein structures in
the Protein Data Bank, but only
some 3,000 of these are unique
(Berman et al., 2000). There are, for
example, hundreds of versions of
lysozyme in the database and there
are many thousands of proteins for
which there are no structural data at
all. Only about 30% of the protein
sequences in SwissProt can be
assigned to a structural class on the
basis of sequence homology to one of
these structural templates. One of
the goals of the structural genomics
initiatives is to provide templates for
the majority of protein sequences
(Sanchez et al., 2000). 
A question for the structural
biologist analogous to the
sequencers’ ‘How many genes are
there in the genome?’ might be ‘How
many protein folds are there?’. One
of the objectives of structural
genomics research is to be able to
relate more directly specific amino
acid sequences with protein folds.
Eventually, when there are a great
deal more real structures available, it
will be possible to predict structures
more easily from primary amino acid
sequence (Thornton et al., 2000).
There is an analogy between the
development of DNA sequencing
and X-ray crystallography that I was
reminded of while reading the
genome papers. DNA sequencing is
based on technology developed by
Fred Sanger over 25 years ago. By a
series of major changes, the most
important of which, from a
throughput point of view, was access
to compute power and the move
from slab to capillary gels, DNA
sequencing went from a laboratory
technique to a high throughput
process. Similar things are happening
in X-ray crystallography.
Eight years ago structure
determination was a slow and
laborious process. The advent of
simple gene cloning techniques and
access to many gene sequences has
allowed the approach of choosing the
same gene from several species as
the starting point to increase the
chances of obtaining a soluble
protein for X-ray analysis, an
approach pioneered by Structural
GenomiX. Proteins can be labeled
with histidine tags and rapid affinity-
based methods used for protein
purification. Automation technology
can then be used for rapid
crystallization set up and viewing,
allowing the production of hundreds
of protein crystals (Abola et al., 2000;
Edwards et al., 2001).
The first publication of the
complete structural proteome of
any organism will be an
interesting read
In the past, structure determination
was carried out using heavy metal
derivatives to solve the phase
problem and allow the interpretation
of the diffraction patterns. Now, with
access to much higher energy
synchrotron radiation at third
generation sites, multi-wavelength
anomalous diffraction (MAD) phasing
methods can be used (Hendrickson et
al., 1989). Proteins are generally
labeled during synthesis with seleno-
methionine for this purpose. Instead
of taking days to collect decent data
sets, sufficient information to derive a
three-dimensional protein structure
can be collected in a few hours or
less. And, as in sequencing, the new
computational power available has
speeded up the process of going from
diffraction pattern to electron density
to structure. Indeed some of this can
now be completed automatically. The
job of the X-ray crystallographer, like
the DNA sequencer, is no longer the
‘doing it’ but the interpretation of
what has been done. Even more
complicated transmembrane proteins
may yield to this kind of structural
genomics approach.
Structural genomics will do
several things for us. By allowing the
determination of structures much
more rapidly than before one can
imagine being able not only to get a
clearer view of fold space but also get
structures of many proteins in the
same family.
From a drug discovery
perspective it is very important to
obtain the structure of many
members of a closely related family
of proteins because it will be possible
to get a three-dimensional view of
many compounds bound to both the
target protein in the family and all
the relatives, some of which may
mediate undesirable, rather than
therapeutic effects.
Another relevant application
would be to obtain systematically the
structure of proteins that are coded
for by open reading frames of no
known function. As the structure
databases increase in size and the
correlation between structure and
function becomes clearer it may be
possible to assign function to
unknown proteins by virtue of their
structure and cross-referencing to
databases of gene expression,
protein–protein interaction and gene
deletion information (see Vidal, 2001)
The first publication of the
complete structural proteome of any
organism will be an interesting read:
for the human genome it would be
just plain beautiful but that vista is
unlikely to be viewed for a little
while yet.
References
Abola E, Kuhn P, Earnest T, Stevens RC:
Automation of X-ray crystallography. Nat
Struct Biol 2000, 7:973-977.
Berman H, Bhat TN, Bourne PE, Feng Z, Gilliland
G, Weissig H, Westbrook J: The Protein
Data Bank and the challenge of structural
genomics. Nat Struct Biol 2000, 7:957-959.
Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt
AR, Collins JE, Bruskiewich R, Beare DM,
Clamp M, Smink LJ, et al.: The DNA
sequence of human chromosome 22.
Nature 1999, 402:489-495.
Edwards A, Arrowsmith CH, Christendat D,
Dharamsi A, Friesen JD, Greenblatt JF,
Vedadi M: Protein production: feeding the
crystallographers and NMR
spectroscopists. Nat Struct Biol 2001,
7:970-972.
R682 Current Biology Vol 11 No 17
Hattori M, Fujiyama A, Taylor TD, Watanabe H,
Yada T, Park HS, Toyoda A, Ishii K, Totoki Y,
Choi DK, et al.: The DNA sequence of
human chromosome 21. Nature 2000,
405:311-319.
Hendrickson WA, Horton JR, Murthy HM, Pahler
A, Smith JL: Multiwavelength anomalous
diffraction as a direct phasing vehicle in
macromolecular crystallography. Basic
Life Sci 1989, 51:317-324.
Hendrickson WA: Synchrotron crystallography.
Trends Biochem Sci 2001, 25:639-643.
International Human Genome Sequencing
Consortium: Initial sequencing and
analysis of the human genome. Nature
2001, 409:860-921.
Nissen P, Hansen J, Ban N, Moore PB, Steitz TA:
The structural basis of ribosome activity
in peptide bond synthesis. Science 2000,
289:920-929. 
The RIKEN Genome Exploration Research
Group: Functional annotation of a full
length mouse cDNA collection. Nature
2001, 409:685-690.
Rubin G, Yandell MD, Wortman JR, Gabor
Miklos GL, Nelson CR, Hariharan IK, Fortini
ME, Li PW, Apweiler R, Fleischmann W,
et al.: Comparative genomics of the
eukaryotes. Science 2000,
287:2204-2215.
Sanchez R, Pieper U, Melo F, Eswar N, Marti-
Renom MA, Madhusudhan MS, Mirkovic N,
Sali A: Protein structure modeling for
structural genomics. Nat Struct Biol 2000,
7:986-990.
Schindler T, Bornmann W, Pellicena P,
Miller WT, Clarkson B, Kuriyan J: Structural
mechanism for STI-571 inhibition of
abelson tyrosine kinase. Science 2000,
289:1938-1942. 
Thornton J, Todd AE, Milburn D, Borkakoti N,
Orengo CA: From structure to function:
approaches and limitations. Nat Struct
Biol 2001, 7:991-994.
Venter JC, Adams MD, Myers EW, Li PW, Mural
RJ, Sutton GG, Smith HO, Yandell M, Evans
CA, Holt RA, et al.: The sequence of the
human genome. Science 2001,
291:1304-1351.
Vidal M: A biological atlas of functional maps.
Cell 2001, 104:333-339.
Address: Structural GenomiX, 10505 Roselle
Street, San Diego, California 92121, USA.
The editors of Current Biology welcome
correspondence on any article in the
journal, but reserve the right to reduce
the length of any letter to be published.
All Correspondence containing data or
scientific argument will be refereed.
Items for publication should either be
submitted typed, double-spaced to: The
Editor, Current Biology, Elsevier
Science London, 84 Theobald’s Road,
London, WC1X 8RR, UK, or sent by
electronic mail to
cbiol@current-biology.com
